Lars H. Lund

Lars H. Lund is a prominent cardiologist and academic who serves as a Professor of Medicine and Chair of the Division of Cardiology at the Karolinska Institutet in Stockholm, Sweden. In tandem with his university leadership, he serves as a Senior Consultant at the Karolinska University Hospital, where he directs the institution's comprehensive heart failure research program. His clinical and research programs focus extensively on heart failure phenotyping across the ejection fraction spectrum, implementing guideline-directed treatments, and spearheading advanced heart failure device and registry-based trials.

Professor Lund has established a massive global footprint in cardiovascular science, authoring over 600 peer-reviewed scientific publications, accumulating more than 90,000 citations, and securing an H-index of 112. His research activities are highly funded by major national and international bodies, including the Swedish Research Council, the Swedish Heart and Lung Foundation, EU Horizon Europe, and the US National Institutes of Health (NIH). Translating his laboratory discoveries into direct therapeutic applications, he identified a novel mechanism to enhance cardiomyocyte calcium sensitivity and founded the biotech and pharmaceutical enterprise AnaCardio to develop targeted heart failure treatments. He has consistently been listed among the world's highest-cited researchers by Clarivate / Web of Science.